Tradestie Institutional Equity Comparison Engine

ABCL vs NOMA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABCL Overall Edge

ABCL Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Momentum & Technical, Options & Structure while NOMA counters with relative strength in Growth & Margin. Fundamentally, ABCL trades at 27.6x Forward P/E with -298.0% operating margin (+18.8% YoY revenue) versus NOMA at N/M Forward P/E and -164.5% operating margin (+122.9% YoY). In options structure, ABCL sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro) against NOMA sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner ABCL
ABCL 27.6x vs NOMA N/M Fwd P/E
Growth & Margin Winner NOMA
Op Margin -298.0% vs -164.5% ยท YoY +18.8% vs +122.9%
Momentum & Technical Winner ABCL
1Y +186.1% vs -88.0% ยท 52W Pos 63% vs 3%
Options & Structure Winner ABCL
BREAKDOWN (24th %ile IV) vs BREAKDOWN (N/A IV)
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$10.47
-4.99% 1D
Market Cap $3.6B
1M Return -14.46%
1Y Return +186.07%
Forward P/E 27.6x
Unified AI Score
58.6 / 100 HOLD
Tech 36.0 Fund 59.0 Flow 70.0 Mom 64.0
NOMA US Equity
NOMA
Institutional Equity
$1.10
-9.84% 1D
Market Cap $22.3M
1M Return -28.57%
1Y Return -87.98%
Forward P/E N/M
Unified AI Score
49.5 / 100 HOLD
Tech 65.0 Fund 61.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABCL +186.07% NOMA -87.98% Spread: +274.05 pp (ABCL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABCL TTM Op. Margin: -298.0% NOMA TTM Op. Margin: -164.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs NOMA. Trailing 12-month operating profitability (ABCL -298.0% vs NOMA -164.5%) and valuation multiples (ABCL 27.6x vs NOMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABCL (7) vs NOMA (3)
Institutional Metric ABCL NOMA Criterion Row Winner
Market Capitalization Scale $3.6B $22.3M Larger Scale ABCL
Trailing P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Forward P/E Ratio Valuation 27.6x N/M Lower Multiple ABCL
Revenue Growth (YoY) Growth +18.8% +122.9% Higher Growth NOMA
Operating Margin (TTM) Profitability -298.0% -164.5% Higher Margin NOMA
Net Profit Margin Profitability -218.6% -213.9% Higher Margin NOMA
Return on Equity (ROE) Capital Efficiency -14.6% -40.7% Higher ROE ABCL
52-Week Range Position Momentum 63% ($3โ€“$15) 3% ($1โ€“$10) Stronger Trend ABCL
Beta / 30D Volatility Risk Regime 2.30ฮฒ ยท 85% Vol -0.45ฮฒ ยท 156% Vol Lower Realized Risk ABCL
Unified Institutional Score Composite Signal 58.6 / 100 (HOLD) 49.5 / 100 (HOLD) Higher Composite ABCL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABCL vs NOMA Buy Guide
ABCL BREAKDOWN
37d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live ABCL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NOMA BREAKDOWN
31d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABCL nor NOMA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.